Mifepristone Access and the Supreme Court: Understanding Louisiana v. FDA

The legal battle over access to mifepristone, a medication used in medication abortions, has returned to the U.S. Supreme Court. At the center of the dispute is the Food and Drug Administration’s (FDA) 2023 policy, which eliminated the requirement that the drug be dispensed in person, thereby allowing it to be prescribed via telehealth and sent through the mail.

Recent rulings from the 5th Circuit Court of Appeals and an emergency intervention by the Supreme Court have created a volatile regulatory environment for healthcare providers and patients across the United States. This case, Louisiana v. FDA, tests the boundaries of federal agency authority and the extent to which states can restrict access to FDA-approved medications.

The Current Legal Timeline: May 2026

The current legal instability stems from a series of rapid-fire court actions in early May 2026:

• May 1, 2026: A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit granted Louisiana’s request to roll back the FDA rules that enabled remote prescribing and mailing. This decision effectively reinstated the in-person dispensing requirement nationwide.
• May 4, 2026: In response to emergency appeals from drug manufacturers Danco Laboratories and GenBioPro, Justice Samuel Alito issued a one-week administrative stay. This stay put the 5th Circuit’s order on hold, temporarily restoring the ability to dispense mifepristone by mail.
• May 11, 2026: The administrative stay is set to expire at 5 p.m. EDT, at which point the Supreme Court’s next move will determine if mail-order access remains legal while the broader case proceeds.

Core Arguments in Louisiana v. FDA

Louisiana’s lawsuit, filed in October 2025, challenges the 2023 Risk Evaluation and Mitigation Strategy (REMS) on several fronts. The state argues that the FDA violated the Administrative Procedure Act (APA) and the Comstock Act—an 1873 law prohibiting the mailing of medications used for abortion.

The Question of Legal Standing

A pivotal issue before the Supreme Court is whether Louisiana has “legal standing” to bring the suit. To have standing, a plaintiff must prove they have suffered a concrete injury that a court decision can fix.

Louisiana asserts that the FDA’s mailing policy undermines the state’s ability to enforce its own abortion bans and creates financial burdens. Specifically, Louisiana cited $92,000 in Medicaid costs paid in 2025 for two women who required emergency care for complications resulting from out-of-state mifepristone.

Conversely, the FDA and manufacturers Danco and GenBioPro argue that Louisiana’s economic harm is too “attenuated” to establish standing. They contend that the FDA regulates drugs, not state legal codes, and that patients could obtain the drug out of state and bring it into Louisiana regardless of the FDA’s mailing policy.

The FDA’s Shifting Position

The FDA is currently navigating a complex political transition. While the agency is defending the lawsuits, the Trump administration’s FDA announced in September 2025 that it was conducting a comprehensive review of mifepristone and the 2023 REMS. The agency stated this review was informed by a “lack of adequate consideration” in prior approvals and recent studies raising safety concerns.

This statement became a critical point of contention. The 5th Circuit relied on it to conclude that the FDA had essentially admitted to failing to comply with the Administrative Procedure Act when it removed the in-person dispensing requirement.

However, the 2023 REMS decision was originally based on over two decades of experience, including a 2021 literature review and five years of adverse data, which the FDA concluded supported the safety of removing the in-person requirement.

Broader Implications for Medication Abortion

The outcome of this case has implications beyond the specific legality of mailing mifepristone.

The Rise of Shield Laws

To counter state-led restrictions, several states have implemented “shield laws.” These laws protect telehealth providers who prescribe and mail mifepristone from their home state to patients in states where abortion is banned. According to the #WeCount project of the Society of Family Planning, approximately 55% of telehealth medication abortions in June 2025 were provided to people living in states with abortion or telemedicine bans.

Alternative Regimens

If the Supreme Court eventually mandates in-person dispensing for mifepristone, some providers may shift to a misoprostol-only regimen. While this is a recognized protocol, medical data indicates it is less effective than the combined mifepristone and misoprostol regimen. Misoprostol-only regimens can cause increased side effects, including greater pain, bleeding, and gastrointestinal distress.

Other State Restrictions

States are increasingly targeting medication abortion through specific legislation:

• Mississippi: A law effective July 1, 2026, makes it unlawful to manufacture, distribute, dispense, or prescribe abortion medication, with penalties up to 10 years in prison.
• Texas: A law allows private citizens to sue entities that provide or transport abortion medication to or from the state.
• Louisiana: A law classifying mifepristone and misoprostol as controlled substances is currently being challenged in state court.

Key Takeaways

Looking Ahead

The Supreme Court’s decision on the emergency appeal will signal how the Court views deference to the FDA on matters of drug safety and approval. Beyond the immediate question of the May 11 deadline, the court must eventually decide if a state can use its own laws to override federal regulations of an approved medication. As interstate conflicts intensify through shield laws and state-level bans, the resolution of Louisiana v. FDA will define the legal landscape of reproductive healthcare for years to come.